Skip to main content

Table 2 Outcome of 63 patients with BSIs due to Candida parapsilosis complex considered in this study

From: Factors related to outcome of bloodstream infections due to Candida parapsilosis complex

Characteristics 30-day outcome
Survival (n = 46) Death (n = 17) P valuea
Age (years), median (IQR)b 62 (31–75) 76 (63–78) 0.046
Male sex, n (%) 24 (52) 11 (65) 0.374
Ward
 Internal Medicine, n (%) 21 (46) 4 (24) 0.033
 Surgery, n (%) 14 (30) 3 (18)  
 Intensive Care Unit, n (%) 11 (24) 10 (59)
Comorbidities, n (%) 40(87) 17(100) 0.117
 Chronic pulmonary diseases, n (%)c 5(11) 4 (24) 0.235
 Haematological malignancy, n (%) 1 (2) 0 (0) 0.540
 Cardiovascular diseases, n (%)d 15 (33) 12(71) 0.006
 Neurological diseases, n (%)e 9 (20) 1(6) 0.263
 Gastrointestinal diseases, n (%)f 16 (35) 5 (29) 0.688
 Diabetes mellitus, n (%) 4 (9) 4 (24) 0.195
 Solid tumors, n (%) 9 (20) 6 (35) 0.193
 Chronic renal failure, n (%) 5 (11) 2 (12) 1.000
Previous surgery (<30 days), n (%) 23(50) 9(53) 0.835
 Gastrointestinal surgery, n (%) 5(11) 3(18) 0.671
 Cardiovascular surgery, n (%) 7(15) 6(35) 0.080
 Other surgery, n (%)g 11(24) 1 (6) 0.154
Central venous catheter, n (%) 41(89) 15 (88) 0.920
 BSI CVC-related, n (%) 25 (61) 11 (73) 0.460
 Early central venous catheter removal, n (%)h 41 (100) 11 (73) <0.0001
Other devices, n (%)i 40 (87) 17(100) 0.178
Previous invasive procedures (<72 h), n (%)j 9 (20) 7 (41) 0.080
Parenteral nutrition, n (%) 29 (63) 14 (82) 0.143
Immunosuppressive therapy, n (%)k 13(28) 5(29) 0.920
Neutropenia, n (%) 3 (7) 1 (6) 1.000
Septic shock, n (%) 1(2) 1(6) 0.470
Prior antibiotic therapy, n (%) 42 (91) 16 (94) 0.713
Previous antifungal therapy, n (%) 4 (9) 1 (6) 0.713
Concomitant bacteriemia, n (%) 12(26) 3(18) 0.487
Other coinfections, n (%)l 28 (61) 11(65) 0.780
Appropriate antifungal therapym 30 (65) 8 (47) 0.190
 Primary azole therapy 32 (70) 9 (53) 0.219
 Primary echinocandin therapy 5 (11) 2 (12) 1.000
 Primary polyene therapy 1 (2) 0 (0) 1.000
 None 8 (17) 6 (35) 0.129
  1. aComparisons between groups were performed using Wilcoxon rank sum test for quantitative variables and Chi-Square test (or Fisher Exact Test when expected frequencies were less than five) for qualitative variables
  2. b IQR, Interquartile range
  3. cChronic pulmonary diseases include asthma, chronic bronchitis, emphysema and lung fibrosis
  4. dCardiovascular diseases include heart failure, ischemic heart disease, endocarditis and arrhythmia
  5. eNeurological diseases include Parkinson’s disease, Alzheimer’s disease and paralysis
  6. fGastrointestinal diseases include Crohn’s disease, ulcerative colitis, chronic pancreatitis and gallbladder stones
  7. gOther surgery includes plastic surgery, thoracic surgery, orthopaedic surgery, urological surgery and neurosurgery
  8. h Early CVC removal was considered occurring within 48 h from blood cultures drawing
  9. i Other devices include urinary catheter, surgical drainage, cutaneous gastrostomy and tracheostomy tube
  10. j Previous invasive procedures include endoscopy and positioning of any device
  11. kImmunosuppressive therapy include corticosteroids, calcineurin inhibitors and monoclonal antibodies
  12. l Other coinfections include bacterial and/or fungal infections in sites other than blood
  13. mAppropriate antifungal therapy was considered when the appropriate drug with adequate dosage was started within 72 h the first blood culture performed